Remedy: Strong Cash flows from Development Fees - Redeye

Redeye comments on Remedy’s Q1 business review. Revenue was EUR 1.3 million above our estimate, EUR 12.7 million versus EUR 11.4 million. The cost base was roughly in line, which resulted in an EBIT somewhat above our estimate.

Länk till analysen i sin helhet: https://www.redeye.se/research/841948/remedy-strong-cash-flows-from-development-fees?utm_source=finwire&utm_medium=RSS